Article

Custom RX initiates voluntary recall of trypan blue

Custom RX Compounding Pharmacy, of Richfield, MN, said it initiated a nationwide recall of trypan blue 0.06% ophthalmic solution, which may be contaminated with Pseudomonas aeruginosa. Use of trypan blue should stop immediately; if applied to eyes, the bacteria could cause serious injury, even blindness, the pharmacy said in a prepared statement posted on the FDA’s Web site.

Custom RX Compounding Pharmacy, of Richfield, MN, said it initiated a nationwide recall of trypan blue 0.06% ophthalmic solution, which may be contaminated with Pseudomonas aeruginosa. Use of trypan blue should stop immediately; if applied to eyes, the bacteria could cause serious injury, even blindness, the pharmacy said in a prepared statement posted on the FDA’s Web site.

Trypan blue, which is packaged in 1-ml sterile tuberculin syringes, was distributed in hospitals and clinics in Maryland, Minnesota, Illinois, Nebraska, North Dakota, Michigan, District of Columbia, and Pennsylvania. The recall includes, but may not be limited to, the following lot numbers: 05042005:86@17, 05252005:36@13, 06282005:91@27, 08012005:63@24, and 08182005:43@17.

Custom RX Compounding Pharmacy is asking that all unexpired syringes be collected and returned to the pharmacy. The pharmacy said it voluntarily recalled the products based on two reports of loss of vision possibly associated with use of the product as reported by the Centers for Disease Control and Prevention and a positive bacterial culture obtained at an outside hospital.

For more details, ophthalmic professionals are asked to contact the pharmacy at 612/866-2211.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.